Top-line Phase 3 Data: Upadacitinib Perfoms Well in Non-segmental Vitiligo
Upadacitinib (Rinvoq, AbbVie) met its primary co-endpoints—The Total Vitiligo Area Scoring Index (T-VASI) 50- and Facial-VASI 75—in patients with non-segmental vitiligo (NSV), according to top-line results from two replicate Phase 3 studies.